The invention relates to improvised pharmaceutical compositions permittingingestion via oraldelivery of proteins/peptides or their conjugates, and/or cation-insulinconjugate complexesdemonstrating desirable pharmacokinetic profiles and potency in efficacymodels of diabetes in dogs andhumans. A preferred formulation comprises 0.01% - 20% w/w of insulin, insulincompound conjugatesand/or cation insulin conjugates, 10% - 60% w/w of one or more fatty acidcomponents selected fromsaturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acidsand additionally containsoptimal amounts of other pharmaceutically suitable polymer excipients whichpermit improved solubility,dissolution rate and effective bioavailability of poorly water solublecompositions and consistent in-vivorelease profiles upon scalability during manufacture . A further aspect of theinvention features theprocess of preparing the aforesaid formulations.
